c Lipstatin, isolated from Streptomyces toxytricini as a potent and selective inhibitor of human pancreatic lipase, is a precursor for tetrahydrolipstatin (also known as orlistat, Xenical, and Alli), the only FDA-approved antiobesity medication for long-term use. Lipstatin features a 2-hexyl-3,5-dihydroxy-7,10-hexadecadienoic-␤-lactone structure with an N-formyl-L-leucine group attached as an ester to the 5-hydroxy group. It has been suggested that the ␣-branched 3,5-dihydroxy fatty acid ␤-lactone moiety of lipstatin in S. toxytricini is derived from Claisen condensation between two fatty acid substrates, which are derived from incomplete oxidative degradation of linoleic acid based on feeding experiments. In this study, we identified a six-gene operon (lst) that was essential for the biosynthesis of lipstatin by large-deletion, complementation, and single-gene knockout experiments. lstA, lstB, and lstC, which encode two ␤-ketoacyl-acyl carrier protein synthase III homologues and an acyl coenzyme A (acyl-CoA) synthetase homologue, were indicated to be responsible for the generation of the ␣-branched 3,5-dihydroxy fatty acid backbone. Subsequently, the nonribosomal peptide synthetase (NRPS) gene lstE and the putative formyltransferase gene lstF were involved in decoration of the ␣-branched 3,5-dihydroxy fatty acid chain with an N-formylated leucine residue. Finally, the 3␤-hydroxysteroid dehydrogenase-homologous gene lstD might be responsible for the reduction of the ␤-keto group of the biosynthetic intermediate, thereby facilitating the formation of the unique ␤-lactone ring.
, structure 1) was originally isolated from fermentation broth of Streptomyces toxytricini as a very potent, selective, irreversible inhibitor of human pancreatic lipase (1, 2) . The saturated derivative of lipstatin, tetrahydrolipstatin ( Fig. 1 , structure 2), commonly known as orlistat, is currently the only available FDA-approved oral drug for long-term treatment of obesity because of its cardiovascular safety and its benefits for diabetes control in obese patients (3, 4) . Orlistat blocks the activity of human pancreatic and gastric lipases, thereby reducing the absorption of fat from diets (5, 6) . Orlistat was also found to exhibit antitumor activity, by virtue of its ability to inhibit the thioesterase domain of fatty acid synthase of tumor cells (7) .
Lipstatin features a 2,3-trans-disubstituted ␤-propiolactone with two linear alkyl chains of C 6 at the ␣-site and C 13 at the ␤-site, respectively (i.e., an ␣-branched 3,5-dihydroxy fatty acid ␤-lactone backbone), and an N-formyl-L-leucine group attached as an ester to the 5-hydroxy of the long chain of the ␣-branched fatty acid backbone (8, 9) (Fig. 1, structure 1) . Opening of the 4-membered ring results in an almost complete loss of the lipase-inhibitory activity of lipstatin, suggesting that the ␤-lactone moiety of the molecule is pivotal to its enzymatic inhibition (10) . Other ␤-lactone natural products produced by microorganisms include esterastin (11, 12) , panclicins (13) , valilactone (14) , and ebelactones (15, 16) , which differ only in the structure of the side chains and the nature of the linked amino acids. For instance, esterastin, a potent inhibitor of lysosomal acid lipase and esterase, has an N-acetyl asparagine side chain instead of an N-formyl-leucine ( Fig. 1, structure 3) (11, 12) .
The biosynthesis of lipstatin in S. toxytricini has been intensively studied based on 15 N, 13 C, and deuterium labeling experiments by the Bacher group (17) (18) (19) (20) (21) . The ␣-branched fatty acid moiety of lipstatin is derived from Claisen condensation between octanoyl coenzyme A (octanoyl-CoA) and 3-hydroxytetradeca-5,8-dienoyl-CoA, both of which are obtained from incomplete ␤-oxidation of linoleic acid (17) (18) (19) (20) (21) . In addition, the H-2 atom of the octanoic acid precursor is displaced with the solvent proton in the final product lipstatin (20) . In contrast, the two longchain fatty acid substrates of the mycolic acids (complex ␣-branched ␤-hydroxy long-chain fatty acids) of mycobacteria and corynebacteria are synthesized by type I and type II fatty acid synthetase systems (FASI and FASII, respectively) (22) . Subsequently, Pks13, a type I polyketide synthase (PKS) with multiple functional domains, takes the two substrates by attaching them to two phosphopantetheine-binding (PPB) domains and catalyzes Claisen condensation between two tethered substrates by the ketosynthase (KS) domain (23) . Furthermore, when [ 13 C-formyl, 15 N]-N-formyl-leucine was fed to S. toxytricini fermentation broth, only the 15 N-leucine moiety of the double-labeled chemical was incorporated into lipstatin, suggesting that the incorporation of leucine takes place after hydrolysis of the formamide motif and that the formyl group is transferred to the L-leucine residue afterwards (21) .
Here we report the identification of the lipstatin biosynthetic operon based on genome sequencing, bioinformatics analyses, and genetic manipulations. A six-gene operon, encoding homologues of two ␤-ketoacyl-acyl carrier protein synthases III (FabH), an acyl-CoA synthetase, a 3␤-hydroxysteroid dehydrogenase, a nonribosomal peptide synthetase (NRPS), and a formyltransferase, was found to be sufficient for the production of lipstatin in Streptomyces. Furthermore, new metabolites were produced by three S. toxytricini gene deletion strains. The model of the lipstatin biosynthetic pathway is updated accordingly.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions. S. toxytricini NRRL15443 was provided by the ARS Culture Collection. Streptomyces lividans TK24 (24) was used as the host for heterologous expression of the lipstatin biosynthetic operon. Escherichia coli DH10B was used for routine cloning experiments. E. coli XL1-Blue MR (Stratagene) was used as the host for construction of the genomic cosmid library. E. coli BW25113/pIJ790 was used for -red-mediated recombination (25) . E. coli ET12567 carrying RK2-derived conjugation helper plasmid pUZ8002 was used as the donor for E. coli-Streptomyces intergeneric conjugation (26) .
pJTU2554 containing an origin of transfer (oriT) from RK2, a functional int-attP (integrase gene-attachment site of phage) region of actinomycete phage C31, and two lambda phage cos sites was used as the vector for the genomic cosmid library (27) . 27F11, a genomic cosmid clone containing 46.5 kb of S. toxytricini genomic DNA including the putative lipstatin biosynthetic operon, was used to construct gene deletion mutants. oriTcontaining plasmid pOJ260 (28), which does not replicate in streptomycetes, was used as a suicide vector for gene replacement in S. toxytricini.
E. coli strains were grown in the Luria-Bertani (LB) broth (29) at 37°C, except for BW25113/pIJ790, which was grown at 30°C. S. lividans strains were grown on MS agar at 30°C for sporulation and conjugation (24) . S. toxytricini strains were grown on International Streptomyces Project Medium 4 (ISP4; BD Biosciences, San Jose, CA, USA) for sporulation and conjugation. Fermentation seed medium (10 g of soya bean flour, 5 g of Bacto soytone, 5 ml of glycerol, 10 ml of soya oil, and 2 ml of Triton X-100 [pH 6.5] per liter) and fermentation medium (30 g of soya bean flour, 14 ml of glycerol, 1 g of Bacto soytone, 1 ml of Triton X-100, and 60 ml of soya oil [pH 7.0] per liter) (30) were used for shake flask fermentation of S. toxytricini and S. lividans strains.
Genomic sequencing and bioinformatics analyses. S. toxytricini NRRL15443 genomic DNA was prepared as described previously (24) . The genome sequence was determined by using the Roche 454 GS (FLX Titanium) sequencing platform. All reads, providing ϳ25-fold genome coverage, were assembled by using Newbler 2.5.3 software (Roche Diagnostics, Branford, CT), and 212 contigs were obtained. The assembled genome sequence was annotated on a high-performance server (NF8560M2; Inspur) with the program Glimmer 3.0 for identification of protein-coding genes (31) . The genes in the lipstatin biosynthetic locus were analyzed by a BLASTp search against the NCBI nonredundant protein sequence, UniProtKB/Swiss-Prot, and Conserved Domain Database (CDD) databases (32) (33) (34) .
S. toxytricini NRRL15443 genomic cosmid library. pJTU2554 vector DNA was digested by BamHI and HpaI, and the resulting cos-containing 6.8-kb and 2.7-kb fragments were gel purified. Genomic DNA of S. toxytricini NRRL15443 was partially digested with Sau3AI, and DNA fractions of 35 to 45 kb were obtained by agarose gel electrophoresis separation and gel extraction. Ligation, competent-cell preparation, library packaging, transfection, storage, and screening of the library were conducted according to standard molecular biology protocols (29) . The genomic library was screened for cosmids that contained DNA of the putative lipstatin biosynthetic operon (lst) by Southern hybridization using a PCR-amplified 429-bp DNA fragment internal to the formyltransferase gene lstF. Oligonucleotides used for PCR amplification of the 429-bp DNA were lstF-F (5=-GTCGCTGGGGCTCCGCATCGT-3=) and lstF-R (5=-TCGGCGACTTCGGGTGCGTG-3=).
Construction of the large-deletion mutant strain SBT11. SBT11, a large-fragment-deletion mutant of S. toxytricini, was generated by removing a 38.4-kb genomic DNA fragment, including the lst operon from the wild-type chromosome, via homologous recombination using a suicide construct, pHTL6. The gene displacement construct pHLTL6 was derived from pOJ260, harboring a 4.9-kb BamHI fragment and a 2.7-kb XbaIBamHI fragment identical to the left and right ends of the S. toxytricini genomic DNA insert of cosmid 27F11, respectively. pHLTL6 was conjugated into S. toxytricini, and offspring single colonies of the exconjugants were screened for double-crossover events, indicated by a loss of apramycin resistance and PCR amplification band patterns. The resulting mutant strain, named SBT11, was verified by PCR experiments to carry the 38.4-kb large-fragment deletion (Table 1 Construction of 27F11-derived integrative plasmids carrying gene deletions. 27F11-derived integrative plasmids carrying deletions in the lst operon and flanking sequences were constructed by -red-mediated recombination (PCR targeting technology) between 27F11 and PCR-amplified DNA fragments harboring the spectinomycin/streptomycin resistance gene aadA (24, 25) . PmeI restriction sites (GAAATTTC) were set in some pairs of oligonucleotides for amplification of the aadA cassette. The aadA cassettes of some 27F11-derived plasmids were removed to generate in-frame deletion mutants, when necessary, by PmeI restriction digestion and religation after -red-mediated recombination (see below). Oligonucleotides for construction and verification of gene deletion mutants are listed in Tables 1 and 2 , respectively.
Thirteen integrative plasmids carrying different gene deletions were generated from integrative cosmid 27F11 by employing these methods. These plasmids included (i) pDelL, in which a 15-kb left-terminal fragment of the genomic DNA insert of 27F11 was deleted; (ii) pDelR, in which a 9-kb right-terminal fragment of the genomic DNA insert of 27F11 was deleted; (iii) pDlstF and pDorf4, in which the open reading frames of lstF and orf4 were replaced by aadA, respectively; and (iv) pDlstA, pDlstB, pDlstC, pDlstD, pDlstE, pDorf1, pDorf2, pDorf3, and pDorf6, in which internal fragments of lstA, lstB, lstC, lstD, lstE, orf1, orf2, orf3, and orf6 were deleted from 27F11, respectively, affording in-frame deletion mutants of these genes.
Construction of S. toxytricini gene deletion mutants. 27F11-derived integrative plasmids carrying deletions in the lst operon and flanking sequences were transferred by E. coli-Streptomyces conjugation into largedeletion mutant strain SBT11 separately. Integration of these plasmids into the chromosome of S. toxytricini SBT11 resulted in the generation of gene disruption strains with deletions in the ectopic copy of the lst genes and adjacent sequences. For instance, integration of pDlstF and pDorf4 into the chromosome of S. toxytricini SBT11 resulted in the generation of the ⌬lstF::aadA and ⌬orf4::aadA mutant strains, respectively. Similarly, S. toxytricini ⌬left, ⌬right, ⌬lstA, ⌬lstB, ⌬lstC, ⌬lstD, ⌬lstE, ⌬orf1, ⌬orf2, ⌬orf3, and ⌬orf6 mutant strains were generated by transferring pDelL, pDelR, pDlstA, pDlstB, pDlstC, pDlstD, pDlstE, pDorf1, pDorf2, pDorf3, and pDorf6, respectively, into SBT11. These mutants were verified by PCR experiments (Table 1; Analysis of lipstatin and new metabolites in fermentation broths. Fermentation broths of wild-type or mutated S. toxytricini strains were treated as described previously (35) . Briefly, 50 ml of fermentation broth of each strain was extracted with 150 ml of acetone-hexane (3:2, vol/vol) four times. The organic phase was combined, dried with sodium sulfate, and concentrated by evaporation to yield a yellow oil with a volume of ϳ1 ml. One hundred microliters of the crude extract was dissolved in 1 ml methanol and centrifuged at 12,000 rpm for 5 min. The supernatant was filtered and subjected to high-performance liquid chromatography (HPLC) or HPLC-mass spectrometry (MS) analysis. HPLC analyses were performed on an Agilent 1260 Infinity HPLC system or an Agilent 1100 series HPLC system (with a diode array detector set at 210 nm). HPLC-MS analysis was performed on the same Agilent 1100 HPLC series instrument coupled with a mass-selective detector (MSD) ion trap mass spectrometry system with an electrospray ionization (ESI) source. HPLC and HPLC-MS were conducted with a Cosmosil Cholester reversed-phase HPLC column Under these conditions, lipstatin was eluted at 16 min when the Agilent 1100 HPLC system was used or at 13.5 min when the Agilent 1260 Infinity HPLC system was used. High-resolution mass spectrometry and nuclear magnetic resonance analyses. High-resolution mass spectrometry (HR-MS) was performed by using a 6530 Accurate-Mass quadrupole time of flight (QTOF) spectrometer coupled to an Agilent 1200 series HPLC system. Nuclear magnetic resonance (NMR) spectra were recorded on an Agilent 500-MHz spectrometer. Proton chemical shifts are reported in ppm (␦) relative to internal tetramethylsilane (TMS) (␦, 0.0 ppm) or with the solvent reference relative to chloroform (CHCl 3 ) (␦, 7.26 ppm). Data are reported as follows: chemical shift (multiplicity [singlet {s}, doublet {d}, triplet {t}, multiplet {m}, and broad singlet {brs}], coupling constants, and integration). Carbon chemical shifts are reported in ppm (␦) relative to TMS with CDCl 3 as the internal standard.
Isolation and structure elucidation of compound 4 from the S. toxytricini ⌬lstF::aadA mutant. The S. toxytricini ⌬lstF::aadA strain was fermented in 4 liters of fermentation medium at 220 rpm at 30°C for 5 days. Mycelium harvested by centrifugation was soaked overnight in 400 ml acetone and extracted three times with 600 ml hexane. The organic phase was combined, dried with sodium sulfate, and concentrated to yield a yellow oil. The yellow crude extract was extracted with 2 volumes of acetonitrile and centrifuged at 12,000 rpm for 5 min. The resulting yellow layer was further purified twice by semipreparative HPLC on an Agilent 1260 Infinity HPLC system under the following elution conditions, where solvent A is H 2 O plus 0.1% formic acid and solvent B is acetonitrile plus 0.1% formic acid: 20% solvent A-80% solvent B from 0 to 10 min, from 20% solvent A-80% solvent B to 10% solvent A-90% solvent B from 10 to 11 min, 10% solvent A-90% solvent B from 11 to 20 min, from 10% solvent A-90% solvent B to 100% solvent B from 20 to 21 min, and 100% solvent B from 21 to 30 min. Compound 4 was eluted at 16.9 min under these conditions. Finally, 22.7 mg of pure compound was obtained. The chemical structure was elucidated based on high-resolution ESI-QTOF-MS, 1 H NMR, 13 C NMR, 1 H-1 H two-dimensional correlated spectroscopy (COSY), distortionless enhancement by polarization transfer at 135°( DEPT135), heteronuclear single quantum coherence (HSQC), and heteronuclear multiple-bond correlation (HMBC) spectra (see Table S1 and Table S1 in the supplemental material for more detailed NMR data).
Isolation and structure elucidation of compound 5 from the S. toxytricini ⌬lstD strain. Compound 5 was isolated from the S. toxytricini ⌬lstD strain by employing the same method as that used for compound 4. Compound 5 was eluted at 25.3 min under the same semipreparative HPLC conditions. Finally, 38.2 mg of compound 5 was purified from 2 liters of fermentation broth. The chemical structure was elucidated based on high-resolution ESI-QTOF-MS, 1 H NMR, 1 H-1 H COSY, 13 C NMR, and DEPT135 spectra (see Tables S2 and S3 and Fig. S7 Tables S2 and S3 in 
RESULTS
Gene organization of the putative lipstatin biosynthetic operon and its downstream region. The genome of S. toxytricini NRRL15443 was sequenced for searching for genes likely to be associated with lipstatin biosynthesis. In the assembled draft genome sequence of S. toxytricini, a nonribosomal peptide synthetase (NRPS) homologue attracted our attention because it was situated next to a formyltransferase homologue. The NRPS homologue showed similarity to many NRPS genes, such as the mycosubtilin synthase subunit C gene (mycC) (36 ) according to prediction by PKS/NRPS analysis (37) . The predicted Stachelhaus code of the A domain of the NRPS was DIFALGGVAK, which shared 70% identity to the signature of leucine-specified A domains (38, 39) . The N-terminal unknown domain (aa 202 to 602) showed marginal similarity (E value, 1.7 ϫ10
Ϫ2
) to the condensation domain of the starting module (CDAPS1_C1_start) of the CDAS1 NRPS governing biosynthesis of the lipopeptide calcium-dependent antibiotic (CDA), with 39% identity over a 59-aa aligned segment (aa 296 to 351 of the query NRPS) when analyzed by using the Natural Product Domain seeker (40) . However, it is worth noting that an HXXXDG catalytic motif, which was reported previously to be essential for the condensation reaction (41, 42) , present in this short aligned region. We therefore named this unknown domain the condensationlike domain (C # domain), on the basis of its low-level similar- 
a Underlined sequences are homologous to the ends of the aadA gene cassette. The PmeI restriction site (gtttaaac, shown in lowercase) in some oligonucleotides was used for removal of the inserted aadA gene cassette by restriction digestion after Red-mediated recombination.
ity, short aligned region, and predicted catalytic motif missing one of the two histidines of canonical condensation domains (HHXXXDG) (41, 42) . Furthermore, the NRPS gene and formyltransferase homologue were located at a six-gene operon, here named lst for putative lipstatin biosynthesis. The relative orientation of the six lst genes (lstA to lstF) and a few downstream genes (orf1 to orf8) are schematically shown in Fig. 2a (top) . lstE is the NRPS homologue. lstF is the formyltransferase homologue. Other genes of the lst operon encode homologues of two ␤-ketoacyl-acyl carrier protein (ACP) synthetases III (FabH) (LstA and LstB), one acyl-CoA synthetase (LstC), and a 3␤-hydroxysteroid dehydrogenase (LstD). The proposed functions, predicted active sites or conserved domains, and BLASTp search results for the six putative Lst proteins (LstA to LstF) and eight downstream gene products (Orf1 to Orf88) are summarized in Table 3 .
Localization of the DNA region essential for lipstatin biosynthesis by large deletion, complementation, and heterologous expression. Genetic experiments, including large deletion and complementation, were carried out to localize the DNA region that was essential for lipstatin biosynthesis. First, a 429-bp fragment internal to lstF, the formyltransferase gene, was used to screen the genomic library by Southern hybridization, resulting in the isolation of 16 cosmids carrying the speculated lst operon. One of them, cosmid 27F11, containing a 46.5-kb insert of genomic DNA including the putative lst operon, was then used to construct a gene replacement vector (pHL6) to generate a large deletion mutant of the S. toxytricini strain via homologous recombination. In the resulting double-crossover strain, SBT11, a 38.4-kb DNA fragment covering the putative lst operon was deleted from the S. toxytricini genome ( Fig. 2a; see also Fig. S1 in the supplemental material). To genetically complement the large deletion, the intattP C31 integrative cosmid 27F11 was transferred into SBT11. The empty vector pJTU2554, as a negative control, was also transferred. S. toxytricini strains SBT11, SBT11/27F11, and SBT11/pJTU2554 and the wild type were fermented under standard conditions, and productions of lipstatin in these strains were analyzed by HPLC. No lipstatin was detected in the organic extract obtained from deletion mutant strain SBT11, and lipstatin production was restored in complementation strain SBT11/27F11 (Fig. 2b, peaks marked by 1) . Furthermore, when 27F11 was transferred into the heterologous host Streptomyces lividans, the resulting exconjugant produced lipstatin although at a yield ϳ30% of that of the original producer S. toxytricini (Fig. 2c, peaks marked  by 1) .
To further narrow down the DNA region needed for lipstatin biosynthesis, a 15-kb left-end fragment and a 9-kb right-end fragment were removed from 27F11 by PCR targeting technology to yield two int-attP C31 integrative plasmids, pDelL and pDelR, respectively (Fig. 2a) . pDelL and pDelR were introduced into SBT11, and the resulting strains were fermented and analyzed by HPLC. Lipstatin was found to be produced in both SBT11/pDelL (⌬left) and SBT11/pDelR (⌬right) (Fig. 2b) . This indicated that the 19.4-kb DNA region shared by pDelL and pDelR, encoding the 6 lst genes and 8 downstream genes, carried the whole set of genes for lipstatin biosynthesis.
Probing the function of the putative lst genes by single-gene knockouts. All 6 genes of the putative lst operon (lstA to lstF) and 5 of 8 genes immediately downstream of the lst operon (orf1, -2, -3, -4, and -6) were disrupted in cosmid 27F11 separately by using PCR targeting technology (Table 2) . Among these genes, lstF and orf4 were disrupted by replacement with a marker gene, aadA. As gene disruption of lstA, lstB, lstC, lstD, lstE, orf1, orf2, orf3, and orf6 by marker insertion or marker replacement would likely cause a polar effect on their downstream genes that might be transcribed from shared promoters, disruptions of these genes were made by in-frame deletion to exclude the probable polar effect. The resulting modified plasmid constructs that carried single-gene disruption mutations were introduced into large-deletion mutant strain SBT11 separately, to afford single-gene-disrupted S. toxytricini strains (see Fig. S2 to S4 in the supplemental material). These strains were fermented and analyzed by HPLC under standard conditions. HPLC analyses showed that lipstatin production was abolished in the ⌬lstA, ⌬lstB, and ⌬lstC single-gene mutants (Fig.  3a) , suggesting that lstA, lstB, and lstC play an essential role in the lipstatin biosynthetic pathway. Meanwhile, the ⌬orf1, ⌬orf2, ⌬orf3, ⌬orf4::aadA, and ⌬orf6 single-gene mutants kept producing lipstatin (Fig. 3a , peaks marked by 1), suggesting that these genes are not involved in biosynthesis.
In the organic extracts obtained from the ⌬lstE and ⌬lstF:: aadA mutants, lipstatin production was not detected in the HPLC-UV and MS chromatograms ( Fig. 3b; see also Fig. S9 in the supplemental material), suggesting that both lstE and lstF are involved in lipstatin production. Furthermore, a new peak (Fig. 3b, asterisks) In the organic extract obtained from the ⌬lstD mutant, lipstatin production was not detected, indicating that lstD is essential for lipstatin production. In addition, a new peak was observed by HPLC analysis (at 21 min) (Fig. 3c, filled circle; Compound 4 accumulated by the S. toxytricini ⌬lstF::aadA strain. The ⌬lstF::aadA strain was fermented (4 liters), and 22.7 mg of the compound was purified from the fermentation broth. The structure of this compound was assigned as (3S,4S,6S)-3-hexyl-4-hydroxy-6-((2Z,5Z)-undeca-2,5-dien-1-yl)tetrahydro-2H-pyran-2-one, on the basis of analysis of the 1 H NMR, 13 C NMR, 1 H-1 H COSY, and HMBC NMR spectroscopic data (compound 4) ( Fig. 4 ; see also Table S1 in the supplemental material). The configurations at C 2 and C 3 were determined to be 2S and 3S based on analysis of the NOESY NMR spectrum, assuming that the configuration at C 5 was 5S (the same as that of lipstatin) (see shifts of 22 carbons and protons matched well with those from the literature, except that the chemical shifts of C 4 and C 6 were exchanged, as supported by two-dimensional NMR spectra (see Table S1 and Fig. S6 in the supplemental material) .
Compound 5 accumulated by the S. toxytricini ⌬lstD strain. The new metabolite accumulated by the ⌬lstD mutant was purified to yield a yellow oil (38.2 mg) readily dissolved in chloroform and acetonitrile. The chemical structure of this metabolite was elucidated as (S)-(S,12Z,15Z)-8-oxohenicosa-12,15-dien-10-yl 2-formamido-4-methylpentanoate (compound 5) (Fig. 4) Tables S2 and S3 
DISCUSSION
In this study, we have identified a six-gene operon that was essential for lipstatin biosynthesis by genetic manipulations. Deletions of lstA, lstB, lstC, lstD, lstE, and lstF all abolished lipstatin production. Meanwhile, both the ⌬lstE and ⌬lstF::aadA mutants produced a new metabolite with the same HPLC retention times, equal molecular masses, and probably identical chemical structures. The metabolite produced by the ⌬lstF::aadA mutant was purified and elucidated as (3S,4S,6S)-3-hexyl-4-hydroxy-6-((2Z,5Z)-undeca-2,5-dien-1-yl)tetrahydro-2H-pyran-2-one (compound 4). In addition, the ⌬lstD mutant produced another new metabolite, which was purified and elucidated as (S)-(S,12Z,15Z)-8-oxohenicosa-12,15-dien-10-yl 2-formamido-4-methylpentanoate (compound 5).
We therefore propose that the LstA, LstB, and LstC enzymes are involved in early steps of the lipstatin biosynthetic pathway, while the LstE, LstF, and LstD enzymes are responsible for the following steps. On the basis of the genetic data, bioinformatics analyses, biosynthetic logics of nonribosomal peptides and fatty acids, and previously reported lipstatin biosynthetic models, we update the lipstatin biosynthetic pathway as follows (Fig. 4) .
Formation of the 22-carbon ␣-branched fatty acid backbone. According to lipstatin biosynthesis models established on the basis of early feeding experiments with S. toxytricini, the first committed step is Claisen condensation between (3S,5Z,8Z)-3-hydroxytetradeca-5,8-dienoyl-CoA and activated octanoic acid to afford the 22-carbon ␣-branched fatty acid backbone (17) (18) (19) (20) (21) . Both substrates of Claisen condensation are obtained from incomplete degradation of linoleic acid. One substrate, 3-hydroxytetradeca-5,8-dienoyl-CoA, is directly obtained from ␤-oxidation. However, in analogy to the initiation of fatty acid synthesis, activation and carboxylation of octanoic acid are needed to form hexylmalonyl-CoA to serve as the second substrate (17) (18) (19) (20) (21) . LstA, LstB, LstC, and a few enzymes from primary metabolism are plausibly involved in these substrate activation and condensation steps. First, the acyl-CoA synthetase homologue LstC might catalyze the ATP-dependent activation of octanoic acid to produce an acyl-CoA thioester via an acyl-adenylate intermediate (46) . The octanoyl-CoA ester is then carboxylated to give hexylmalonyl-CoA, probably by an acyl-CoA carboxylase (ACCase) complex, the inactivation of which caused a decrease of lipstatin production by ϳ80% in S. toxytricini (30) . An unknown route may be present to complement the ACCase pathway for the generation of hexylmalonyl-CoA, however. The hexylmalonylCoA thioester is then transferred to ACP borrowed from primary metabolism. The resulting hexylmalonyl-ACP serves as one of two substrates for Claisen condensation. The C 14 substrate of the condensation, as mentioned above, is directly obtained from the incomplete degradation of linoleic acid. Next, LstA, probably together with LstB, both of which are FabH homologues, catalyzes the decarboxylation of hexylmalonyl-ACP and successive condensation with 3-hydroxyl-5,8-tetradecadienoyl-CoA to afford a 3-keto-5-hydroxy-C 22 -ACP intermediate (compound 6) (Fig. 4) . Double-FabH homologues may be employed to incorporate unusual starter units into final products in some biosynthetic pathways, for instance, AsuC3/C4 in the asukamycin production pathway (51) . Substrate selectivity and stereochemistry of LstAB and LstC enzymology will be subjects of further research. Nevertheless, the formation of ␣-branched ␤-hydroxylated fatty acid derivative in S. toxytricini is different from the synthesis of mycolic acids in corynebacteria and mycobacteria, which is carried out by a multifunctional type I polyketide synthase, Pks13 (23) .
Incorporation of formyl and leucine groups into the 3-keto-5-hydroxy-C 22 -ACP intermediate. The subsequent steps are the incorporation of leucine and formyl groups into the 3-keto-5-hydroxy-C 22 -ACP intermediate (21) . Accumulation of compound 4 in the ⌬lstE and ⌬lstF::aadA mutants supports that the NRPS LstE and the formyltransferase LstF are responsible for the attachment of leucine and formyl groups and that the attachment occurs after Claisen condensation. First, LstE might activate leucine with ATP to form a leucinyl-AMP intermediate by the A domain and then load the activated leucinyl group onto the PCP domain at the serine-attached 4=-phospho-pantethine side chain as a thioester. LstF then transfers a formyl group to the ␣-amine group of the PCP-tethered leucine residue to form a PCP-tethered formyl-leucine. Finally, LstE might catalyze the nucleophilic attack of the 5-hydroxyl of intermediate compound 6 on the acyl carbon of the PCP-tethered formyl-leucine by its C # domain to yield intermediate compound 7, probably via a mechanism analogous to that of acyltransferase reactions (Fig. 4 , curved arrow) (41) . Thus, because of the absence of either functional LstE or LstF proteins in the ⌬lstE and ⌬lstF::aadA mutant strains, the free 5-hydroxy of the 3-keto-5-hydroxy-C 22 -ACP intermediate (compound 6) attacks on the C-1 carbonyl to give a ␦-lactone derivative spontaneously (52) . The 3-keto of the resulting ␦-lactone derivative might be reduced by LstD or an unknown enzyme to give compound 4 (see below).
Reduction of the 3-keto group and formation of ␤-lactone. The next steps are reduction of the 3-keto group and formation of the ␤-lactone to afford the final product lipstatin. The production of metabolite 5 in the ⌬lstD mutant supports that the reduction of the 3-keto group and the formation of ␤-lactone are the final steps leading to lipstatin. In addition, the displacement of the H-2 proton with the solvent proton, which was shown by deuterium feeding experiments, may also occur before the formation of ␤-lactone (20) . The LstD protein sequence is similar to those of many members of the 3␤-hydroxysteroid dehydrogenase extended-shortchain dehydrogenase/reductase (3␤-HSD-like eSDR) superfamily, such as Rv1106c (53) . It is worth noting that the characterized 3␤-HSD from animals is a bifunctional dehydrogenase/isomerase enzyme (54) . Therefore, it is plausible that LstD is involved in the reduction of the 3-keto group to a 3-hydroxyl group, which is probably also involved in the exchange of the H-2 proton with the solvent proton by an unknown mechanism. After the 3-keto is reduced, the resulting 3-hydroxy group may attack spontaneously on the carbonyl moiety of the ACP-tether acyl intermediate to give the ␤-lactone ring, in analogy with the formation of the ␤-lactone ring in the ebelactone biosynthesis pathway (55) . On the other hand, the production of compound 4 in the ⌬lstE and ⌬lstF::aadA mutants implies that the LstD dehydrogenase might also reduce the 3-keto group to a 3-hydroxyl in the absence of a 5-O-formylleucine group to afford compound 4, or another, unknown enzyme in S. toxytricini contributes to this reduction. The catalytic mechanism and substrate specificity of LstD will be the subjects of further research.
